XERS (Mkap $144 M) Cash $124 M --Biotech mit Potential
eröffnet am 17.02.20 16:28:22 von
neuester Beitrag 11.11.22 22:57:41 von
neuester Beitrag 11.11.22 22:57:41 von
Beiträge: 248
ID: 1.320.409
ID: 1.320.409
Aufrufe heute: 0
Gesamt: 32.097
Gesamt: 32.097
Aktive User: 0
ISIN: US98422L1070 · WKN: A2JPE9
2,3800
USD
-3,64 %
-0,0900 USD
Letzter Kurs 06.10.21 NYSE
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2298 | +22,98 | |
| 8,8000 | +20,22 | |
| 0,6000 | +17,62 | |
| 6,3800 | +16,85 | |
| 6,5600 | +15,09 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,1840 | -11,32 | |
| 1,0900 | -11,38 | |
| 0,9939 | -15,77 | |
| 3,2110 | -16,60 | |
| 1,0000 | -16,67 |
Beitrag zu dieser Diskussion schreiben
Feedback
11.11.
Xeris Biopharma posts record 3Q revenue as more patients utilize its treatments
https://www.proactiveinvestors.com/companies/news/998145/xer…
...
The company reported record net product revenue of $29.6 million, up 17% quarter-over-quarter and 31% year-over-year on a pro forma basis
Xeris Biopharma Holdings (NASDAQ:XERS) Inc has announced record third-quarter financial results and subsequently raised its 2022 year-end cash balance guidance.
The company reported record net product revenue of $29.6 million, up 17% quarter-over-quarter and 31% year-over-year on a pro forma basis. Cash on hand, equivalents and short-term investments totaled $93.4 million as of September 30
“Our third quarter and year-to-date performance reflect the continued strength of our growing commercial products coupled with disciplined management of our cash,” CEO Paul Edick said in a statement. “This gives us confidence to raise our year-end cash balance guidance to $110-$120 million, reaffirm and tighten net product revenue range to $105-110 million for full year, and reaffirm our guidance of $50 million in synergies and cash flow breakeven by year-end 2023."
READ: Xeris Biopharma reveals Phase 3 SONICS study data evaluating Recorlev for Cushing's syndrome
“As we finish the year and head into 2023, we expect to build upon our 2022 momentum and continue creating shareholder value through continued revenue growth, careful allocation of resources, and prudent expense management,” he added.
On an individual product basis, the company saw net revenue of $13.7 million from Gvoke, compared to $11 million a year earlier. Prescriptions for the glucagon injection topped 38,000 for the first time, up more than 41% compared to the same period in 2021.
Net revenue from Keveyis was $13.4 million, a 17% jump from the third quarter of 2021 on a pro forma basis. The number of patients on Keveyis increased by 9% over the same period.
Recorlev saw third-quarter net revenue of $2.5 million, thanks in large part to increases in the number of patients on therapy.
Net loss for the quarter was $21.8 million, $0.16 per share, the company said.
Looking ahead, Xeris said it will participate at the Jefferies London Healthcare Conference, held November 15-17 in London and the Piper Sandler 34th Annual Healthcare Conference, held November 29-December 1 in New York.
...
=>
Xeris Biopharma posts record 3Q revenue as more patients utilize its treatments
https://www.proactiveinvestors.com/companies/news/998145/xer…
...
The company reported record net product revenue of $29.6 million, up 17% quarter-over-quarter and 31% year-over-year on a pro forma basis
Xeris Biopharma Holdings (NASDAQ:XERS) Inc has announced record third-quarter financial results and subsequently raised its 2022 year-end cash balance guidance.
The company reported record net product revenue of $29.6 million, up 17% quarter-over-quarter and 31% year-over-year on a pro forma basis. Cash on hand, equivalents and short-term investments totaled $93.4 million as of September 30
“Our third quarter and year-to-date performance reflect the continued strength of our growing commercial products coupled with disciplined management of our cash,” CEO Paul Edick said in a statement. “This gives us confidence to raise our year-end cash balance guidance to $110-$120 million, reaffirm and tighten net product revenue range to $105-110 million for full year, and reaffirm our guidance of $50 million in synergies and cash flow breakeven by year-end 2023."
READ: Xeris Biopharma reveals Phase 3 SONICS study data evaluating Recorlev for Cushing's syndrome
“As we finish the year and head into 2023, we expect to build upon our 2022 momentum and continue creating shareholder value through continued revenue growth, careful allocation of resources, and prudent expense management,” he added.
On an individual product basis, the company saw net revenue of $13.7 million from Gvoke, compared to $11 million a year earlier. Prescriptions for the glucagon injection topped 38,000 for the first time, up more than 41% compared to the same period in 2021.
Net revenue from Keveyis was $13.4 million, a 17% jump from the third quarter of 2021 on a pro forma basis. The number of patients on Keveyis increased by 9% over the same period.
Recorlev saw third-quarter net revenue of $2.5 million, thanks in large part to increases in the number of patients on therapy.
Net loss for the quarter was $21.8 million, $0.16 per share, the company said.
Looking ahead, Xeris said it will participate at the Jefferies London Healthcare Conference, held November 15-17 in London and the Piper Sandler 34th Annual Healthcare Conference, held November 29-December 1 in New York.
...
=>
Paul Edick, CEO von Xeris Biopharma Holdings, Inc. (XERS) zu den Ergebnissen des 4. Quartals 2021 – Protokoll der Telefonkonferenz.
https://seekingalpha.com/article/4494564-xeris-biopharma-hol…
lg tz
https://seekingalpha.com/article/4494564-xeris-biopharma-hol…
lg tz
Xeris Biopharma gibt US-amerikanische FDA-Zulassung von Recorlev® (Levoketoconazol) zur Behandlung endogener Hypercortisolämie bei erwachsenen Patienten mit Cushing-Syndrom bekannt.
https://finance.yahoo.com/news/xeris-biopharma-announces-u-f…
lg tz.
https://finance.yahoo.com/news/xeris-biopharma-announces-u-f…
lg tz.
Antwort auf Beitrag Nr.: 70.357.817 von Blitzableiter am 30.12.21 22:59:59Xeris anticipates year-end cash, cash equivalents, and investments of approximately $100 million
“Continued strong demand for both Gvoke and Keveyis resulted in outstanding growth in third quarter, recording pro forma net sales of $22.5 million. Our two commercial brands are now on track to achieve a combined $76-80 million in full year revenue,” said Paul R. Edick, Chairman and CEO of Xeris Biopharma.
Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous Cushing’s syndrome for which an NDA has been filed and subsequently accepted by the FDA with a PDUFA date of January 1, 2022. Strongbridge puts the peak sales potential of Recorlev between $250 million to $350 million.
“Continued strong demand for both Gvoke and Keveyis resulted in outstanding growth in third quarter, recording pro forma net sales of $22.5 million. Our two commercial brands are now on track to achieve a combined $76-80 million in full year revenue,” said Paul R. Edick, Chairman and CEO of Xeris Biopharma.
Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous Cushing’s syndrome for which an NDA has been filed and subsequently accepted by the FDA with a PDUFA date of January 1, 2022. Strongbridge puts the peak sales potential of Recorlev between $250 million to $350 million.
Habe heute 20.000 Stück zu 2,49 USD gekauft. War wohl ein Volltreffer.
Egal wie stark der Kurs morgen steigen wird, ich werde langfristig halten.
Habe mir die Firma sehr genau angeschaut. Die haben bereits zwei zugelassene Produkte, die zusammen schon ca, 100m Umsatz generieren. Nun wurde das dritte Produkt zugelassen. Weitere Produkte sind in der Pipeline. Zweistellige Kurse sind absolut realistisch.
Egal wie stark der Kurs morgen steigen wird, ich werde langfristig halten.
Habe mir die Firma sehr genau angeschaut. Die haben bereits zwei zugelassene Produkte, die zusammen schon ca, 100m Umsatz generieren. Nun wurde das dritte Produkt zugelassen. Weitere Produkte sind in der Pipeline. Zweistellige Kurse sind absolut realistisch.
Trading Spotlight
Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) wird voraussichtlich einen Quartalsumsatz von 20,67 Millionen US-Dollar bekannt geben !!!
https://www.marketbeat.com/instant-alerts/nasdaq-xers-consen…
Handel wurde angehalten.
lg tz.
https://www.marketbeat.com/instant-alerts/nasdaq-xers-consen…
Handel wurde angehalten.
lg tz.
Xeris Pharmaceuticals schließt Kooperationsvereinbarung mit Merck.
[urlhttps://finance.yahoo.com/news/xeris-pharmaceuticals-enters-collaboration-agreement-113000209.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAHW1gTxjUOYJE2lqwteUvFMZIvw8n-a7iEgLbZiILxpgWaiXqAamgsBlor2BHgLChbvr9FtC0Ok8cs_apq98DbwGzw-6lcK7B2ATiarHR-3B0nliYjXbCQ1TUrRerheFIWxbohxs9do1a31Qc8JmZYpvbg87ycFI3PPl08xWOq0s][/url]
lg tz
Ganz schöne verwässerung …
Die im Rahmen der Transaktion zu zahlende Gegenleistung für Aktien und bedingte Wertrechte („CVRs“), einschließlich des im Rahmen der CVRs zu zahlenden maximalen Gesamtbetrags, bewertet Strongbridge mit ungefähr 267 Millionen US-Dollar, basierend auf dem Schlusskurs der Xeris-Stammaktien von 3,47 US-Dollar am 21. Mai 2021 und das vollständig verwässerte Aktienkapital von Strongbridge. Gemäß den Bedingungen der Transaktion wurde jede zum Abschluss der Transaktion ausstehende Stammaktie von Strongbridge in das Recht umgewandelt, ein festes Umtauschverhältnis von 0,7840 Stammaktien von Xeris Biopharma Holdings und 1 nicht handelbaren CVR im Wert von mehr zu erhalten auf zusätzliche 1,00 USD zahlbar in bar oder in Stammaktien von Xeris Biopharma Holdings (nach Wahl von Xeris Biopharma Holdings) bei Erreichen der folgenden auslösenden Ereignisse: (i) die Notierung von mindestens einem erteilten Patent für KEVEYIS® in der Orange Book bis Ende 2023 oder mindestens 40 Millionen US-Dollar Jahresnettoumsatz von KEVEYIS® im Jahr 2023 (0,25 US-Dollar pro Stammaktie), (ii) Erreichen von mindestens 40 Millionen US-Dollar Jahresnettoumsatz von RECORLEV® im Jahr 2023 (0,25 US-Dollar pro Stammaktie) und (iii) Erzielung eines jährlichen Nettoumsatzes von RECORLEV® in Höhe von mindestens 80 Millionen US-Dollar im Jahr 2024 (0,50 US-Dollar pro Stammaktie). Die Mindestzahlung auf den CVR pro Strongbridge-Stammaktie beträgt null und die maximale Zahlung beträgt nach Wahl von Xeris Biopharma Holdings 1,00 USD in bar oder Stammaktien von Xeris Biopharma Holdings.Nach Abschluss der Transaktion besitzen die ehemaligen Xeris-Aktionäre etwa 60 % der Xeris Biopharma Holdings, während die ehemaligen Strongbridge-Aktionäre etwa 40 % besitzen
Xeris Pharmaceuticals schließt Übernahme von Strongbridge Biopharma ab!
Xeris Pharmaceuticals, Inc. und Strongbridge Biopharma plc sind jetzt Tochtergesellschaften von Xeris Biopharma Holdings, Inc. (Nasdaq: XERS).
https://www.businesswire.com/news/home/20211005006055/en/Xer…
Ich befürchte es geht jetzt erst mal Richtung Süden.
lg tz
Xeris Pharmaceuticals, Inc. und Strongbridge Biopharma plc sind jetzt Tochtergesellschaften von Xeris Biopharma Holdings, Inc. (Nasdaq: XERS).
https://www.businesswire.com/news/home/20211005006055/en/Xer…
Ich befürchte es geht jetzt erst mal Richtung Süden.
lg tz
Durchsuchen
